Sodium Carbonate → 5-(11-fluoro-6-(hydroxymethyl)-6H-pyrido[2',3':5,6][1,3]oxazino[3,4-a]indol-2-yl)-2-(6-methoxypyridin-3-yl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide
Reaktionsgleichung
Cl[C:2]1[CH:3]=[CH:4][C:5]2[O:18][CH:17]([CH2:19][OH:20])[N:8]3[C:9]4[CH:10]=[CH:11][CH:12]=[C:13]([F:16])[C:14]=4[CH:15]=[C:7]3[C:6]=2[N:21]=1.[CH3:22][O:23][C:24]1[N:29]=[CH:28][C:27]([C:30]2[O:31][C:32]3[CH:42]=[C:41]([N:43]([CH3:48])[S:44]([CH3:47])(=[O:46])=[O:45])[C:40](B4OC(C)(C)C(C)(C)O4)=[CH:39][C:33]=3[C:34]=2[C:35]([NH:37][CH3:38])=[O:36])=[CH:26][CH:25]=1.C(=O)([O-])[O-].[Na+].[Na+].CC(C1C=C(C(C)C)C(C2C=CC=CC=2P(C2CCCCC2)C2CCCCC2)=C(C(C)C)C=1)C>O1CCOCC1.O.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd]>[F:16][C:13]1[C:14]2[CH:15]=[C:7]3[C:6]4[N:21]=[C:2]([C:40]5[C:41]([N:43]([CH3:48])[S:44]([CH3:47])(=[O:46])=[O:45])=[CH:42][C:32]6[O:31][C:30]([C:27]7[CH:28]=[N:29][C:24]([O:23][CH3:22])=[CH:25][CH:26]=7)=[C:34]([C:35]([NH:37][CH3:38])=[O:36])[C:33]=6[CH:39]=5)[CH:3]=[CH:4][C:5]=4[O:18][CH:17]([CH2:19][OH:20])[N:8]3[C:9]=2[CH:10]=[CH:11][CH:12]=1Komponenten
Edukt 4
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 3
Reaktionsbedingungen
- Temperatur
- 70 °C
Versuchsvorschrift
To a solution of (S or R)-(2-chloro-11-fluoro-6H-pyrido[2′,3′:5,6][1,3]oxazino[3,4-a]indol-6-yl)methanol (35 mg, 0.115 mmol), 2-(6-methoxypyridin-3-yl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzofuran-3-carboxamide (50 mg, 0.097 mmol) and sodium carbonate (20 mg, 0.188 mmol) in 2 mL of 1,4-dioxane and 0.2 mL of water was added Pd2(dba)3 (10 mg) and X-Phos (10 mg) under nitrogen. The reaction mixture was heated at 70° C. for 16 hours and concentrated in vacuo to remove 1,4-dioxane. And then the residue was suspended in water and extracted with EtOAc. The combined organic phase was washed with brine, dried over Na2SO4 and concentrated. The residue was purified by prep-HPLC to give the product of (S or R)-5-(11-fluoro-6-(hydroxymethyl)-6H-pyrido[2′,3′:5,6][1,3]oxazino[3,4-a]indol-2-yl)-2-(6-methoxypyridin-3-yl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (30 mg, yield: 47%). 1H-NMR (CDCl3, 400 MHz) δ 8.72 (d, J=2.4 Hz, 1H), 8.14˜8.17 (m, 1H), 7.99 (s, 1H), 7.64 (s, 1H), 7.43˜7.48 (m, 2H), 7.14˜7.23 (m, 3H), 6.81˜6.86 (m, 2H), 6.42˜6.45 (m, 1H), 6.06 (brs, 1H), 4.01 (s, 3H), 3.98˜4.00 (m, 1H), 3.85˜3.88 (m, 1H), 3.37 (s, 3H), 2.96 (d, J=4.8 Hz, 3H), 2.72 (s, 3H), 2.27 (s, 1H). MS (M+H)+: 658.
Aufarbeitung
- concentrationconcentrated in vacuo
- customto remove 1,4-dioxane
- extractionextracted with EtOAc
- washThe combined organic phase was washed with brine
- dry with materialdried over Na2SO4
- concentrationconcentrated
- customThe residue was purified by prep-HPLC
Quellen und Nachweise
- ORD-Eintrag
- ord-2905b0fd7d5a4e90b1f8097366b082ef
- Quelldatensatz
- uspto-grants-2016_01
- Patentnummer
- US09242998B2
Notizen zur Reaktion
Wird geladen…